5′-triphosphate non-linear RNA for selective cancer cell death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA-sensing PRR agonists for cancer treatment face limitations due to non-specific induction of immune reactions, leading to toxicity and reduced therapeutic efficacy, as they activate both cancer and normal cells, causing inflammatory cytokine production that can promote tumor growth and organ damage.
Innovation Solution
Development of 5′-triphosphate non-linear RNA compositions, such as 2′-fluoromodified pyrimidine-containing ssRNA or dsRNA with specific stem-loop structures, which selectively induce cell death and differential cytokine expression in cancer cells, minimizing toxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA-sensing PRR agonists are used to induce cell death in cancer cells, then cytotoxicity is improved, but non-specific induction of immune reactions causes toxicity to normal cells
Solution Approach 1:
The patent applies local quality by designing RNA compositions with specific structural features (stem-loop configurations, 5′-triphosphate modifications, specific nucleotide sequences) that are recognized preferentially by PRRs in cancer cells versus normal cells. This localized structural differentiation enables selective activation of immune responses in target cells while sparing non-target cells, resolving the contradiction between cytotoxicity and normal cell toxicity.
Solution Approach 2:
The patent employs parameter changes by modifying key characteristics of the RNA compositions including secondary structure (stem-loop vs linear), chemical modifications (2′-fluoromodified pyrimidines, phosphorothiolated nucleotides), and 5′-end modifications (triphosphate vs monophosphate). These parameter variations create differential recognition profiles that enhance cancer cell selectivity while maintaining immunogenic cell death activity.
2Reliability
If PRR agonists activate both cancer and normal cells, then immune response is improved, but inflammatory cytokine production promotes tumor growth and organ damage
Solution Approach 1:
The patent applies segmentation by dividing the immune response into distinct functional components: cytotoxicity induction versus cytokine production. The RNA compositions are designed to segment the activation pathway such that cell death is triggered through direct PRR engagement while cytokine production is modulated through controlled signaling pathways, thereby achieving immune activation without excessive inflammatory responses that would promote tumor growth.
Solution Approach 2:
The patent converts the potentially harmful non-specific immune activation into a beneficial selective response. By designing RNA compositions that exploit differences in PRR expression or signaling capacity between cancer and normal cells, the harmful broad activation is transformed into a beneficial targeted response that eliminates cancer cells while minimizing damage to normal tissues and avoiding tumor-promoting inflammation.
Data Source
AI summary
Disclosed herein are compositions and methods for inhibiting the growth of cells or inducing cell death. The composition capable of inhibiting the growth of cells or inducing cell death comprises a 5′-triphosphate non-linear RNA. The RNA comprises a first stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and may optionally comprise a second stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and a spacer between the first stem-loop and the second stem loop. Methods for inhibiting the growth of cells or inducing cell death comprise contacting cells with the composition or administering the composition to a subject in an amount effective to inhibit the growth of the cells or induce death of the cells.